![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 40, 37612-37618, October 4, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
§,
¶,
**,

,
§§,
,
,
, and
¶¶
From the
Department of Pathology, University of Utah
Health Sciences Center, Salt Lake City, Utah 84132 and the
Department of Biology, Georgetown University, Washington D. C. 20057
Received for publication, June 20, 2002, and in revised form, July 19, 2002
| |
ABSTRACT |
|---|
|
|
|---|
The yeast PHO2 gene encodes a
homeodomain protein that exemplifies combinatorial control in
transcriptional activation. Pho2 alone binds DNA in vitro
with low affinity, but in vivo it activates transcription
with at least three disparate DNA-binding proteins: the zinc finger
protein Swi5, the helix-loop-helix factor Pho4, and Bas1, an myb-like
activator. Pho2 + Swi5 activates HO, Pho2 + Pho4 activates
PHO5, and Pho2 + Bas1 activates genes in the purine and
histidine biosynthesis pathways. We have conducted a genetic screen and
identified 23 single amino acid substitutions in Pho2 that
differentially affect its ability to activate its specific target
genes. Analysis of the mutations suggests that the central portion of
Pho2 serves as protein-protein interactive surface, with a requirement
for distinct amino acids for each partner protein.
Eukaryotic genomes encode a large number of DNA-binding factors.
There are 168 and 104 genes encoding homeodomain DNA-binding proteins
in humans and Drosophila, respectively, and 607 and 232 genes for zinc finger DNA-binding proteins in these two organisms (1).
However, many of these proteins contain very similar DNA-binding domains and may recognize the same DNA sequence in vitro.
The Drosophila homeodomain proteins have been well analyzed,
and although genetic studies show that these proteins activate
different sets of genes in vivo, in vitro
DNA-binding experiments show that many of these proteins recognize very
similar DNA sequences (2). This apparent conundrum has led to the view
that regulatory specificity results from increased DNA binding
specificity through cooperative interactions between multiple
transcription factors. Cooperativity between transcription factors acts
positively to increase affinity and specificity in promoter site
recognition (3). Combinatorial mechanisms also allow a transcription
factor to act at different genes by interacting with multiple distinct partners.
The yeast PHO2 gene (also known as BAS2 or
GRF10) encodes a homeodomain transcription factor that
activates transcription in a combinatorial manner. It appears that Pho2
does not act alone, but with several partner proteins. By itself, Pho2
binds DNA with low affinity (4) and comparison of in vitro
binding sites reveals a relatively nonspecific consensus, ATTA or TAAT
(4-6), similar to the consensus for Drosophila homeodomain
proteins (2).
Pho2 binds DNA cooperatively with the Pho4 helix-loop-helix factor to
activate expression of the PHO5 acid phosphatase (7). Similarly, Pho2 and the Swi5 zinc finger protein bind cooperatively to
the HO promoter and contribute to its transcriptional
activation (4, 8, 9). Bas1, an myb-like transcription factor, works with Pho2 in the activation of a set of biosynthetic genes, including HIS4, ADE1, and ADE5,7 (5, 10-12).
In vitro studies have not shown cooperative DNA binding
between Bas1 and Bas2 (13), however, these experiments were conducted
with in vitro expressed proteins that may not reflect their
native state in vivo (14). Additionally, two-hybrid analyses
detect an interaction between Pho2 and each of its partners, Pho4,
Bas1, and Swi5 (9, 15-17), and Pho2 Bas1 interaction has been
demonstrated by co-immunoprecipitation (18).
Previous experiments have identified specific amino acids in Swi5 that
are important for cooperativity with Pho2, because Swi5 mutant alleles
with substitutions at these residues are defective in both cooperative
DNA binding and transcriptional activation (9). In this report we
describe a reciprocal but expanded strategy to identify Pho2 amino acid
residues with discrete roles in activation of a subset of its target
genes due to specific defects in individual partner protein interactions.
Strains--
The strains used in this study are listed in Table
I. Strains DY1921, DY2187, and DY5075 are
isogenic strains in the W303 strain background. The HO(Site
B)-CYC1::lacZ reporter integrated at
the URA3 locus has been described previously (9), except that in DY5075 LEU2 was inserted into URA3 using
plasmid pUL9 (19), a ura3:LEU2 converter. Strains RR87 and
RR88 are isogenic in the S288C background and have been previously
described (15).
Plasmids--
The plasmids used in this study are listed in
Table I, except for the plasmids with PHO2 point mutations,
which are listed in Table II. Plasmid M3570 contains a
HindIII fragment with PHO2 cloned into a pRS316
(YCp-URA3) derivative that lacks the BamHI site in the
polylinker. M3589 was constructed from M3570 by site-directed mutagenesis with primers F471 (CAATACAGGGATCCCCAC) and F470
(TTCAGGATCCTTTTCCC) to introduce BamHI sites that make
conservative amino acid substitutions (F273L and A422G). Thus, plasmid
M3589 has two BamHI sites, at amino acids 273 and 442 of the
PHO2 insert. Plasmid M2295 with an HIS4-lacZ
reporter was constructed by cloning a 5-kb SalI fragment with HIS4-lacZ into a YRp-TRP1 plasmid. Plasmid
pL10-2x was prepared by cloning a fragment of ~8 kb SalI
to BspE1 encoding ADE5,7-lacZ into the SalI and
XmaI sites of a derivative of pRS314 lacking the
NaeI to NcoI fragment encoding
lacZ Isolation of PHO2 Mutants--
Residues 171 to 503 of
PHO2 were PCR-amplified using oligonucleotides F400
(CTTCATCCATATTTCACGATGAAG) and F401 (GCATTATGATTGTTATTGCTGTTG) using an
error-prone mutagenesis protocol as described (9). PCR products were
transformed into strain DY5075, along with the gapped plasmid
(BamHI-digested M3589), and Ura+ transformants were
selected. Following replica plating, the transformants were screened
for defects in interaction with Swi5, Pho2, and Bas1 as follows: The
HO(Site B)-lacZ reporter requires Swi5 and Pho2 for
activation, and reporter activity was examined using the chromogenic substrate 5-bromo-4-chloro-3- Other Methods--
Site-directed mutagenesis by the dut-
ung- method was performed as described (22), and all mutations
were confirmed by dideoxy sequencing. Extracts were prepared and
quantitative assays for A Screen for PHO2 Mutants
Strain DY5075 was designed to allow simultaneous screening of
PHO2 mutations that affect activation of specific target
genes, HO, HIS4, and PHO5. In addition
to a PHO2 gene disruption, the strain has an integrated
HO(Site B)-lacZ reporter, which contains the Swi5 binding
site from the Site B region of the HO promoter acting as a
UAS driving expression of lacZ. This reporter turns SWI5
PHO2 colonies blue in the presence of the chromogenic substrate X-gal, but either a swi5 or a pho2 mutation
causes colonies to remain white (9). HIS4 expression can be
activated either by the Pho2/Bas1 pathway or by the Gcn4 pathway (5).
This strain has mutations in both PHO2 and GCN4,
and thus it is a histidine auxotroph. Finally, PHO5
expression depends on PHO2, and this strain is unable to
grow in the absence of inorganic phosphate. Thus, DY5075 has a White,
His-, Pho- phenotype, but transformation with a PHO2 plasmid
results in a Blue, His+, Pho+ phenotype.
Deletion analysis demonstrated that the DNA-binding domain of Pho2 is
not sufficient for cooperative DNA binding with Swi5 at the
HO promoter (25). Amino acids 77-136 comprise the Pho2 homeodomain DNA-binding domain (see Fig.
1), and a large C-terminal region was
shown to be required for interaction with Swi5 in vitro. To
more precisely identify the regions of Pho2 that interact with its
partner proteins, we decided to isolate Pho2 point mutations that
interfered with its ability to activate specific target genes. Our
strategy combined PCR-mediated random mutagenesis with plasmid gap
repair (26) to generate a mutagenized plasmid library of PHO2.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
Strain and plasmid list
. Plasmid pR335 with an lexAop-lacZ reporter was
constructed by inserting a DNA fragment with TRP1 into the
ApaI site of the URA3 gene of plasmid pSH18-34 (20). Plasmid p2099 expressing an LexA-Bas1 fusion protein has been
described previously (15).
-D-galactopyranoside
(X-gal)1 in a blue/white
colony lift assay (21). Poor growth on -Ura-Ade and -Ura-His
plates was used to assess a defect in activation of Ade or His
biosynthetic genes by Bas1 and Pho2. Additionally, limited growth on
media lacking inorganic phosphate was used to assess defect in
PHO5 activation by Pho4 and Pho2. Mutants showing defects in
all phenotypic assays tested were discarded as likely null mutants.
Plasmids were then isolated after passage through Escherichia
coli and re-transformed into DY5075 to confirm phenotypes.
-galactosidase activity were performed using
the chromogenic reagent
o-nitrophenyl-
-D-galactopyranoside as
described (23). Low phosphate media was prepared, and phosphatase
assays were performed as described (24). Western immunoblots were
performed with anti-Pho2 and anti-Pgk1 antibodies and developed with an ECL Western kit (Amersham Biosciences). The rabbit antisera to Pho2 was
generated against an His-tagged Pho2 fusion protein expressed from
plasmid M2025 (4), and the rabbit anti-Pgk1 antibody was from Molecular
Probes Inc. The immunoblots were quantitated with IMAGE software
(National Institutes of Health, rsb.info.nih.gov/nih-image/), and the
Pho2 protein levels were normalized to Pgk1.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (23K):
[in a new window]
Fig. 1.
Screen for Pho2 mutations. A,
the Pho2 mutation is represented schematically, showing the DNA-binding
and activation domains. The acidic region from 286 to 326 is
hatched. The positions of the Pho2 point mutations are
marked, with seven of the mutations listed. The PHO2 region
corresponding to amino acids 171-504 was amplified using mutagenic
PCR conditions and transformed along with BamHI-cleaved
plasmid M3589, which is missing amino acids 273-442. The homology
between the PCR product and the gapped plasmid allows in
vivo recombination resulting in a circular plasmid. B,
the DY5075 strain contains three Pho2-dependent genes, the
HO(Site B)-lacZ reporter activated by Swi5 and Pho2, the
HIS4 gene activated by Bas1 and Pho2, and the
PHO5 gene activated by Pho4 and Pho2.
A fragment of Pho2 encoding amino acids 171-504 was subjected to error-prone PCR (Fig. 1). The PCR product was then co-transformed into yeast along with plasmid M3589 that had been cleaved with BamHI. This digestion creates a linearized yeast plasmid with a gap between codons 273 and 422 (Fig. 1). In vivo recombination using the homology between the PCR product and the linearized plasmid repairs the gap and allows formation of a circular plasmid, whereas the URA3 marker on the plasmid allows for selection of these events. Co-transformation of DY5075 with the PHO2 PCR product and linearized M3589 resulted in Ura+ transformants that were screened for either decreased Blue color on X-gal (the White phenotype), reduced growth on media lacking histidine (the His- phenotype), or reduced growth on media lacking inorganic phosphate (the Pho- phenotype). Any mutant showing either a White, His-, or Pho- phenotype was re-screened by the original assay and screened by the other two phenotypic assays. Clearly, a vast majority of these PHO2 mutations were characterized as White, His-, Pho- phenotypes and subsequently discarded as potential null mutants. We only retained mutants where activation of at least one of the reporters was greater than a pho2 null mutant strain carrying the URA3 vector.
A total of 12,000 yeast transformants containing plasmids bearing potential mutations in Pho2 were screened, and 290 candidates with either decreased expression of the HO(Site B)-lacZ reporter, decreased growth on -His plates, or decreased growth on -Pho plates were identified. After DNA purification, re-transformation and testing in vivo phenotypes, 40 were subjected to DNA sequence analysis. Some clones had single mutations, whereas other clones had multiple amino acid substitutions. Among the group with multiple mutations, clones with single amino acid substitutions were generated either by subcloning or by site-directed mutagenesis. We created a set of 23 YCp-URA3 plasmids, each with a single amino acid substitution in PHO2.
Pho2 Mutation Sites and Protein Levels
Although a 334-amino acid region in the center of the protein from 171 to 504 was subjected to mutagenesis, we observed that the mutations tended to fall in two regions (Fig. 1). The first region of ~30 residues was defined by four mutations in positions 244-270, and the second region of ~50 residues was defined by 16 mutations in positions 343-390. Two mutations are on the edge of an acidic patch from 286 to 326 that lies between the two clusters of mutations, and one mutation is found at position 415 in a region implicated in activation function (15).
Western immunoblots were performed to determine whether the point
mutations in Pho2 affected protein levels. Yeast strain DY5075 was
transformed with plasmids containing the various Pho2 mutants, the
wild-type PHO2 gene or the vector control. Extracts were
prepared from log phase cells and size-separated on SDS gels for
immunoblot analysis (Fig. 2). The blots
were probed with antibody specific to Pho2, as well as with as an
antibody to Pgk1 as an internal loading control. The results were
quantified and are listed in Fig. 2. Most of the Pho2 mutants are
expressed at normal levels (defined as expressing between one-fourth to
2-fold of wild-type), with the exception of L244S, F258L and F259L,
which showed a severe reduction in Pho2 protein levels (<5%), and
F270L and H390L, which showed a strong reduction (10-15%). With the exception of H390L, all of the mutations that exhibit a strong or
severe decrease in Pho2 protein levels are found in a cluster of
mutation amino-terminal to the acidic patch. Because these mutations
have a strong effect on Pho2 protein levels, and most likely can
account for the decrease in gene expression detected, we have largely
excluded them from the analyses below.
|
Analysis of Pho2 Point Mutants
Pho4-dependent Expression-- The secreted acid phosphatases are encoded by three genes, PHO5, PHO11, and PHO10 (27). The better studied of these, PHO5, encodes the major form, whereas the other two genes encode minor species. The expression of these genes is repressed when cells are grown in medium containing inorganic phosphate, and derepression requires the activity of Pho4 and Pho2 (27). To determine the ability of the Pho2 mutants to activate expression of these genes, we measured acid phosphatase activity in cellular extracts (Table II) and normalized the expression data to both wild-type expression and Pho2 protein levels. Ten of the remaining eighteen mutations greatly affected expression of the secreted phosphatases (less than 26% activity remaining). These ten mutations are found tightly clustered between positions 347 and 378 and exhibit phosphatase activities that are undetectable and up to 20% of the wild-type. Phosphatase expression was affected in strains with the mutations F347L, V349G, C369Y, D370G, D371G, D371N, F372L, E374G, E374V, and V378G. Interestingly, each of these mutations also affect expression of the Swi5- and Bas1-dependent reporters (described below), indicating that these mutations either alter the overall structure of the region, or affect critical contacts required for all three partners. We did not identify any Pho2 alleles that specifically diminished phosphatase expression (Pho4-dependent) while retaining expression of the other reporters.
|
Swi5-dependent Expression--
Strain DY5075 contains
the integrated HO(Site B)-lacZ reporter, the
expression of which is dependent on Swi5 and Pho2. We next determined
the effect of the PHO2 mutations on expression of this
reporter. Extracts were prepared from log phase cells and used for
quantitative
-galactosidase assays (Table II).
-Galactosidase activities are presented as specific activities and as a percentage normalized to the PHO2 wild-type and Pho2 protein levels.
Fourteen mutations in PHO2 affected expression of this
reporter leading to
-galactosidase activities that were less than
26% of wild-type. These mutations include the ten substitutions
described above that affect acid phosphatase expression and mutations
N387S, I388V, and I415V. The N363S mutation strongly affected
expression of HO(Site B)-lacZ and the two
Bas1-dependent reporters (see below) but only weakly
affected phosphatase expression. Strikingly, mutations in the adjacent
residues N387S and I388V strongly decreased expression of
HO(Site B)-lacZ. These two mutations had only a
moderate affect on the expression of the other reporters (expression
was decreased to 52-80%) or they retained expression at wild-type or
higher levels. I415V lies farther to the C terminus than all of the
other mutations and strongly affects both the HO(Site
B)-lacZ and HIS4-lacZ reporters. Thus, we can
provisionally identify two positions within Pho2, amino acids N387 and
I388, as making specific contacts with Swi5.
Bas1-dependent Expression-- Almost twenty genes require the combination of Bas1 and Pho2 for expression, including genes required for metabolism of histidine, purine, and pyrimidine nucleotides and one-carbon units (5, 10-12). The HIS4 gene is activated by one of two pathways, either by Pho2 in combination with Bas1 or by Gcn4 acting alone (5). The ADE5,7 gene is activated by Bas1 and Pho2 but does not require Gcn4 (10, 28). The HIS4 and ADE5,7 genes also differ in their dependence on Pho2 in an assay based on activation by Bas1-VP16 (17); HIS4 expression is strongly dependent on Pho2, whereas ADE5,7 exhibits a moderate requirement. Several other ADE genes, typified by ADE1, have only a weak dependence on Pho2 (17).
To determine the ability of the Pho2 mutants to activate
HIS4 expression, a gcn4 pho2 strain was
transformed with a HIS4-lacZ reporter plasmid and
the set of Pho2 plasmids. Extracts were prepared from log phase cells
and used for quantitative
-galactosidase assays (Table
III).
-Galactosidase activities are
presented as normalized to the PHO2 wild-type and Pho2
protein levels. Eleven mutations exhibited substantial decreases in
expression of HIS4-lacZ, largely overlapping with the ones
described above that affect phosphatase expression. The Pho2 mutations
R343K, F347L, V349G, N363S, C369Y, D370G, F372L, V378G, and I415V (but
not the mutations at E374) strongly affected HIS4-lacZ
expression. In addition to these mutations, R343K is strongly decreased
for HIS4 expression, expressing only 2% of the wild-type
level, and two mutations, D319A and K331G, appear to have completely
lost the ability to activate HIS4 expression with Bas1,
exhibiting empty-vector levels of
-galactosidase activity. These
mutations are located within or immediately adjacent to the acidic
region (positions 286-326). Finally, the I388V mutation described
above as showing a strong decrease in expression of HO(Site
B)-lacZ when paired with Swi5, exhibited a 3.25-fold
increase in HIS4-lacZ expression relative to WT
Pho2. Thus, mutations D319A, K331G, and R343K appear to be specific for
Bas1.
|
To determine the ability of the Pho2 mutants to activate
ADE5,7 expression, an ADE5,7-lacZ
reporter plasmid and the set of Pho2 plasmids were transformed into a
pho2 strain (RR87). Cells were grown in the absence of added
adenine to induce expression of ADE genes, and extracts were
prepared for quantitative
-galactosidase assays (Table III).
-Galactosidase activities are presented as normalized to the
PHO2 wild-type and Pho2 protein levels. In general, the same
set of mutations that affected HIS4-lacZ expression also affected expression of ADE5,7-lacZ except for the three
Bas1-specific alleles, D319A, K331G, and R343K, which had essentially
normal levels of ADE5,7-lacZ expression. The finding that
these latter three alleles exhibited a significant decrease only at
HIS4-lacZ could be a result of HIS4 having a
strong requirement for Pho2 (17) or that strain background differences
affect expression. The D371G mutation, which was only mildly affected
for HIS4-lacZ expression, did not promote
ADE5,7-lacZ expression above background.
One-hybrid Assay for Interaction-- The analysis of the Pho2 mutations described above has revealed two alleles specific for Swi5 (N387S and I388V) and three alleles that affect expression of one or both of the Bas1-dependent reporters (D319A and K331G). Because the Pho2 mutations affect gene expression but do not co-localize with the DNA-binding domain or the activation domain, we postulate that these mutations affect interaction with partners. One test for partner interaction is based on a one-hybrid assay using a LexA-Bas1 fusion protein (15). In these experiments, LexA-Bas1 activates expression of a lexAop-lacZ reporter, but this activation sharply decreases in the absence of Pho2. Thus, the activation by LexA-Bas1 is dependent upon Pho2, but the Pho2 DNA-binding domain is not required for this stimulation.
To test our Pho2 mutants for the ability to interact with Bas1 with
this assay, the set of plasmids with Pho2 mutations was transformed
along with a lexAop-lacZ reporter plasmid into strain RR88 (pho2 bas1-2) expressing the LexA-Bas1
fusion protein. Cells were grown in the absence of added adenine, which stimulates the Bas1-Pho2 interaction, and extracts were prepared for
quantitative
-galactosidase assays (Table
IV).
-Galactosidase activities are
presented as normalized to the PHO2 wild-type and Pho2
protein levels. Four mutations showed substantially reduced activation
of the reporter by LexA-Bas1, suggesting that these Pho2 mutants are
defective in Bas1 interaction, or in activation per se.
Interestingly, the V349G mutation strongly affects HIS4-lacZ expression with only a modest effect at ADE5,7-lacZ, whereas
the N363S shows the opposite pattern; both of these mutations exhibited about the same level of lexAop-lacZ
expression. Interestingly, two Pho2 alleles, S367A and N387S, exhibited
a severe defect in activating the
lexAop-lacZ reporter (<2% expression) but they exhibited only mild effects on the HIS4-lacZ and
ADE5,7-lacZ reporters. In general, this assay appeared to
better correlate more closely with the expression pattern from the
ADE5,7-lacZ reporter, rather than the
HIS4-lacZ reporter. Two alleles, K331G and E374G, exhibited
a greater than 2-fold increase in expression, which did not reflect the
expression patterns of either HIS4-lacZ or
ADE5,7-lacZ. Finally, this assay failed to detect the
strongly decreased expression seen at both HIS4-lacZ and
ADE5,7-lacZ with the Pho2 alleles F347L, D370G, and
F372L.
|
We have conducted three assays to examine how the Pho2 mutations affect
interaction with Bas1, at HIS4-lacZ and
ADE5,7-lacZ with native Bas1 and at
lexAop-lacZ with LexA-Bas1. In general,
the three assays gave similar results for the twenty-two mutations, although specific differences were detected (D319A and K331G
at HIS4-lacZ versus S367A and N387S at
lexAop-lacZ). Although it may be possible
that differences in the genetic background or growth conditions
affected our interpretation, an intriguing possibility is that the
expression differences among the Pho2 mutant alleles reflect the
different binding contexts with Bas1.
| |
DISCUSSION |
|---|
|
|
|---|
The Pho2 protein provides a model for combinatorial control of transcriptional regulation. Pho2 binds DNA very poorly on its own but works with three distinct partner proteins, the Swi5 zinc finger protein, the Pho2 helix-loop-helix protein, and the Bas1 myb-like protein. In this report we identify and characterize Pho2 point mutations that selectively affect the ability of Pho2 to activate transcription with different partner proteins.
We previously conducted a deletion analysis of Pho2 to determine what regions are required for cooperative DNA-binding in vitro with Swi5 (25). These studies showed that the DNA-binding domain (amino acids 77-136) of Pho2 is not sufficient for cooperative DNA binding and that a large C-terminal region was required for interaction with Swi5 in vitro. Interestingly, truncations that remove part of this region are unstable in E. coli, and these C-terminal truncation polypeptides expressed from an in vitro transcription/translation system are unable to even bind DNA, despite the fact that the homeodomain DNA-binding region is intact. These results suggest that this C-terminal region of Pho2 comprises a specific protein domain and that deletion endpoints within this region cause aberrant protein folding. Studies by Berben et al. (29) demonstrated that a C-terminal truncation of residues past 407 is still functional in vivo for PHO5 activation, whereas a truncation of residues before 404 is completely inactive. We conclude from these studies that the domain of Pho2 required for partner interaction is within amino acids 170-407. Importantly, the point mutations we obtained, which selectively affect activation of reporters with the Swi5, Pho2, and Bas1 partner proteins, lie within this region. These results are consistent with two-hybrid experiments showing that amino acids 112-404 of Pho2 are required for interaction with Bas1 (18).
Fig. 3 compares the effect of the Pho2
point mutations on expression of HO-lacZ, acid phosphatase,
HIS4-lacZ, and ADE5,7-lacZ. Several mutations
(L244S, F258L, F259L F270L, and H390L) are not considered in Fig. 3,
because they strongly affect protein levels (see Fig. 2). Three of
these substitutions are a relatively conservative change of
phenylalanine for leucine, but they imparted a severe effect on protein
stability. Considering this observation in light of the stability and
folding problems discussed above for truncations expressed in E. coli and in vitro, these findings suggest that the
correct folding of this region requires contributions by very specific
amino acids.
|
Mutations in a region of Pho2 from positions 343 to 390 affect expression of the reporter genes. Notably, within this region is a set of tightly clustered mutations, C369Y, D370G, D371G, D371N, F372L, E374G, and E374V, that affect five of six positions and perhaps form the core of the interaction region, because the reporters for all partners showed strong effects on expression. A second cluster, positions 387-390, is found just C-terminal to the core. Mutations here show more specificity: N387S is specifically affected for HO(Site B)-lacZ expression, and, interestingly, I388V exhibits a strong decrease in HO(Site B)-lacZ expression but a 3.25-fold increase in HIS4-lacZ expression. A third cluster within this region lies N-terminal to the core at 343-349 and adjacent to the mutations that showed specificity for HIS4-lacZ expression (D319A and K331G). Taken together, the region from 343 to 390 appears to be principally involved in partner interaction, with many amino acid substitutions having general affects and a small number of substitutions having specific affects.
We also were able to investigate effects of the Pho2 mutations with a single partner, Bas1, in three unique contexts, at HIS4-lacZ, ADE5,7-lacZ, and lexAop-lacZ. Particularly interesting are the mutations D319A, K331G, and R343K, which severely affect HIS4-lacZ expression, and S367A and N387S, which severely affect lexAop-lacZ expression; these five mutations exhibit only mild effects on expression with the other two Bas1-dependent reporters. That we detected strong effects on expression unique for the context suggests that Bas1 and Pho2 do not form the same kind of ternary complex with DNA at each promoter. Although this may be expected when Pho2 forms a ternary complex with the LexA-Bas1 fusion protein, it is interesting that we could detect this context dependence at two reporters using native Bas1. These results fit nicely with the experiment of Pinson et al. (17) who used a Bas1-VP16 fusion protein to investigate the requirement for Pho2/Bas2 at HIS4 and several ADE promoters. In their experiment they showed that Bas1-VP16 strongly required Pho2 to activate HIS4-lacZ expression, it modestly required Pho2 to activate ADE5,7-lacZ, and it had nearly no requirement for Pho2 to activate the other ADE reporters. Our results here also support the findings of Barbaric et al. (7) who showed that the requirement for Pho2 is different at UASp1 of the PHO5 promoter than at UASp2. At UASp1, Pho2 cooperates with Pho4 to allow binding, but at UASp2 Pho2 is required for transactivation by Pho4. Together, these results suggest that Pho2 has different ways to cooperate with each of its partners to determine ternary complex formation and activation function at each unique promoter context.
This analysis has provided a detailed description of mutations in Pho2
that affect its function with three different co-regulators and has
provided new insights into the structure of this interesting protein,
required for expression of nearly two dozen genes in Saccharomyces. This collection of Pho2 mutants should be a
useful set of reagents to further explore the role of protein-protein interactions in combinatorial control of gene expression.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Fang Zhang for assisting with the initial screen, YiWei Jiang for providing plasmid M2295, Shengzhong Lu for providing plasmid pL10-2x, and Helen McBride for preparing the anti-Pho2 antibody.
| |
FOOTNOTES |
|---|
* This work was supported by National Science Foundation-Career Grant MCB9734170 (to R. J. R.) and National Institutes of Health Grant R01-GM48624 (to D. J. S.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ Present address: Myriad Genetics, Inc., Salt Lake City, UT 84108.
¶ Present address: College of Osteopathic Medicine, University of Health Sciences, Kansas City, MO 64106.
** Present address: University of California Santa Barbara, Santa Barbara, CA 93016.

Present address: Wake Forest University School of Medicine,
Winston-Salem, NC 27157.
§§ Present address: Arizona College of Osteopathic Medicine, Phoenix, AZ 85308.
¶¶ To whom correspondence should be addressed: Dept. of Pathology, University of Utah, 30 North 1900 East, Rm5C126 SOM, Salt Lake City, UT 84132-2501. Tel.: 801-581-5429; Fax: 801-581-4517; E-mail: david.stillman@path.utah.edu.
Published, JBC Papers in Press, July 26, 2002, DOI 10.1074/jbc.M206125200
| |
ABBREVIATIONS |
|---|
The abbreviations used are:
X-gal, 5-bromo-4-chloro-3-
-D-galactopyranoside;
ANOVA, analysis
of variance.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Venter, J. C.,
Adams, M. D.,
Myers, E. W., Li, P. W.,
Mural, R. J.,
Sutton, G. G.,
Smith, H. O.,
Yandell, M.,
Evans, C. A.,
Holt, R. A.,
Gocayne, J. D.,
Amanatides, P.,
Ballew, R. M.,
Huson, D. H.,
Wortman, J. R.,
Zhang, Q.,
Kodira, C. D.,
Zheng, X. H.,
Chen, L.,
Skupski, M.,
Subramanian, G.,
Thomas, P. D.,
Zhang, J.,
Gabor Miklos, G. L.,
Nelson, C.,
Broder, S.,
Clark, A. G.,
Nadeau, J.,
McKusick, V. A.,
Zinder, N.,
Levine, A. J.,
Roberts, R. J.,
Simon, M.,
Slayman, C.,
Hunkapiller, M.,
Bolanos, R.,
Delcher, A.,
Dew, I.,
Fasulo, D.,
Flanigan, M.,
Florea, L.,
Halpern, A.,
Hannenhalli, S.,
Kravitz, S.,
Levy, S.,
Mobarry, C.,
Reinert, K.,
Remington, K.,
Abu-Threideh, J.,
Beasley, E.,
Biddick, K.,
Bonazzi, V.,
Brandon, R.,
Cargill, M.,
Chandramouliswaran, I.,
Charlab, R.,
Chaturvedi, K.,
Deng, Z., Di,
Francesco, V.,
Dunn, P.,
Eilbeck, K.,
Evangelista, C.,
Gabrielian, A. E.,
Gan, W., Ge, W.,
Gong, F., Gu, Z.,
Guan, P.,
Heiman, T. J.,
Higgins, M. E., Ji, R. R., Ke, Z.,
Ketchum, K. A.,
Lai, Z.,
Lei, Y., Li, Z., Li, J.,
Liang, Y.,
Lin, X., Lu, F.,
Merkulov, G. V.,
Milshina, N.,
Moore, H. M.,
Naik, A. K.,
Narayan, V. A.,
Neelam, B.,
Nusskern, D.,
Rusch, D. B.,
Salzberg, S.,
Shao, W.,
Shue, B.,
Sun, J.,
Wang, Z.,
Wang, A.,
Wang, X.,
Wang, J.,
Wei, M.,
Wides, R.,
Xiao, C.,
Yan, C.,
et al..
(2001)
Science
291,
1304-1351 |
| 2. | Laughon, A. (1991) Biochemistry 30, 11357-11372[CrossRef][Medline] [Order article via Infotrieve] |
| 3. | Wolberger, C. (1998) Curr. Opin. Genet. Dev. 8, 552-559[CrossRef][Medline] [Order article via Infotrieve] |
| 4. |
Brazas, R. M.,
and Stillman, D. J.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
11237-11241 |
| 5. |
Arndt, K. T.,
Styles, C.,
and Fink, G. R.
(1987)
Science
237,
874-880 |
| 6. |
Barbaric, S.,
Munsterkotter, M.,
Svaren, J.,
and Horz, W.
(1996)
Nucleic Acids Res.
24,
4479-4486 |
| 7. |
Barbaric, S.,
Munsterkotter, M.,
Goding, C.,
and Horz, W.
(1998)
Mol. Cell. Biol.
18,
2629-2639 |
| 8. | McBride, H. J., Brazas, R. M., Yu, Y., Nasmyth, K., and Stillman, D. J. (1997) Mol. Cell. Biol. 17, 2669-2678[Abstract] |
| 9. |
Bhoite, L. T.,
and Stillman, D. J.
(1998)
Mol. Cell. Biol.
18,
6436-6446 |
| 10. |
Rolfes, R. J.,
Zhang, F.,
and Hinnebusch, A. G.
(1997)
J. Biol. Chem.
272,
13343-13354 |
| 11. |
Daignan-Fornier, B.,
and Fink, G. R.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
6746-6750 |
| 12. | Denis, V., Boucherie, H., Monribot, C., and Daignan-Fornier, B. (1998) Mol. Microbiol. 30, 557-566[CrossRef][Medline] [Order article via Infotrieve] |
| 13. |
Tice-Baldwin, K.,
Fink, G. R.,
and Arndt, K. T.
(1989)
Science
246,
931-935 |
| 14. | Pinson, B., Gabrielsen, O. S., and Daignan-Fornier, B. (2000) Mol. Microbiol. 36, 1460-1469[CrossRef][Medline] [Order article via Infotrieve] |
| 15. | Zhang, F., Kirouac, M., Zhu, N., Hinnebusch, A. G., and Rolfes, R. J. (1997) Mol. Cell. Biol. 17, 3272-3283[Abstract] |
| 16. | Hirst, K., Fisher, F., McAndrew, P. C., and Goding, C. R. (1994) EMBO J. 13, 5410-5420[Medline] [Order article via Infotrieve] |
| 17. |
Pinson, B.,
Kongsrud, T. L.,
Ording, E.,
Johansen, L.,
Daignan-Fornier, B.,
and Gabrielsen, O. S.
(2000)
Nucleic Acids Res.
28,
4665-4673 |
| 18. | Hannum, C., Kulaeva, O. I., Sun, H., Urbanowski, J. L., Wendus, A., Stillman, D. J., and Rolfes, R. J. (July 10, 2002) J. Biol. Chem. 10.1074/jbc.M206168200 |
| 19. | Cross, F. R. (1997) Yeast 13, 647-653[CrossRef][Medline] [Order article via Infotrieve] |
| 20. |
Finley, R. L., Jr.,
and Brent, R.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
12980-12984 |
| 21. | Dohrmann, P. R., Voth, W. P., and Stillman, D. J. (1996) Mol. Cell. Biol. 16, 1746-1758[Abstract] |
| 22. | Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. E., Seidman, J. G., Smith, J. A., and Struhl, K. (1987) Current Protocols Molecular Biology , pp. 8.1.1-8.1.6, Wiley and Sons, New York |
| 23. | Breeden, L., and Nasmyth, K. (1987) Cell 48, 389-397[CrossRef][Medline] [Order article via Infotrieve] |
| 24. |
Dorland, S.,
Deegenaars, M. L.,
and Stillman, D. J.
(2000)
Genetics
154,
573-586 |
| 25. |
Brazas, R. M.,
Bhoite, L. T.,
Murphy, M. D., Yu, Y.,
Chen, Y.,
Neklason, D. W.,
and Stillman, D. J.
(1995)
J. Biol. Chem.
270,
29151-29161 |
| 26. | Muhlrad, D., Hunter, R., and Parker, R. (1992) Yeast 8, 79-82[CrossRef][Medline] [Order article via Infotrieve] |
| 27. | Oshima, Y., Ogawa, N., and Harashima, S. (1996) Gene 179, 171-177[CrossRef][Medline] [Order article via Infotrieve] |
| 28. |
Rolfes, R. J.,
and Hinnebusch, A. G.
(1993)
Mol. Cell. Biol.
13,
5099-5111 |
| 29. | Berben, G., Legrain, M., and Hilger, F. (1988) Gene 66, 307-312[CrossRef][Medline] [Order article via Infotrieve] |
| 30. | Jiang, Y. W., and Stillman, D. J. (1995) Genetics 140, 103-114[Abstract] |
| 31. |
Sikorski, R. S.,
and Hieter, P.
(1989)
Genetics
122,
19-27 |
This article has been cited by other articles:
![]() |
I. Som, R. N. Mitsch, J. L. Urbanowski, and R. J. Rolfes DNA-Bound Bas1 Recruits Pho2 To Activate ADE Genes in Saccharomyces cerevisiae Eukaryot. Cell, October 1, 2005; 4(10): 1725 - 1735. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-J. Huang, J.-G. Chang, S.-C. Wu, and K.-B. Choo Negative Transcriptional Modulation and Silencing of the Bi-exonic Rnf35 Gene in the Preimplantation Embryo: BINDING OF THE CCAAT-DISPLACEMENT PROTEIN/Cux TO THE UNTRANSLATED EXON 1 SEQUENCE J. Biol. Chem., September 2, 2005; 280(35): 30681 - 30688. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Gardocki, M. Bakewell, D. Kamath, K. Robinson, K. Borovicka, and J. M. Lopes Genomic Analysis of PIS1 Gene Expression Eukaryot. Cell, March 1, 2005; 4(3): 604 - 614. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |